Dr. Ellebrecht presented "PIK3CD as a Niche Checkpoint of Human Skin T Cell Residence." The inventor of the CAAR T cell concept, and a @penncoltoncenter.bsky.social pilot awardee, his lab decodes how T cells commit to long- or short-lived fates to engineer precision cellular #immunotherapies.
The Colton Consortium for Autoimmunity has received a $15M, three-year investment from the Colton Foundation to advance autoimmune disease research across NYU Langone Health, Yale School of Medicine, and Tel Aviv University.
Read the full announcement: www.coltonconsortium.org/blog/colton-...
Stefan Feske, MD (NYU Grossman School of Medicine) will be speaking at next week's session of the Colton Consortium Virtual Speaker Series (3/17, 11AM ET) on "IFN-γ-Producing Th1 Cells and Treg Cells in Sjögren's Disease." Open to #autoimmunity + #immunology researchers.
Register: bit.ly/4bBeUaT
Led by Drs. Cherry, Fajgenbaum and Miner, HIT-AI uses knowledge graphs, ML and high-throughput screening to identify repurposed treatments across 160+ autoimmune diseases, evaluating 4,000 FDA-approved drugs from screening to clinical trials — a scalable model for the future of #autoimmunity.
Join us next Tuesday (May 19, 11am ET) for the Colton Consortium Virtual Seminar featuring Montserrat Anguera, PhD (Penn Vet) who will be covering "Sex Differences in Autoimmune Disease: Xist RNA-Mediated Mechanisms That Influence B Cell Function." Registration required: https://bit.ly/4wwhLdP
Join us April 21 at 11 AM ET for the Colton Consortium Virtual Speaker Seminar ft. Ruslan Medzhitov, PhD of the Yale School of Medicine. Dr. Medzhitov will discuss how environmental factors shape adaptive immunity and their implications for inflammation, allergy, and disease.
https://bit.ly/4mo4yyW
Today, the 2026 Penn Colton Center for #Autoimmunity Symposium brings together the Penn #autoimmune research community—spanning diverse disease areas and the full continuum of discovery—to share new insights in diagnosing, treating, and preventing autoimmune diseases.
New in Nature: Penn Medicine researchers, led by Dr. Katalin Susztak, revealed a subtype of diabetic kidney disease driven by B cell immune clusters — linked to faster kidney failure. The study also introduces a gene-based signature and blood test that could help identify high-risk patients earlier
Don't miss this month's installment of the Colton Consortium Virtual Speaker Series, featuring Yaakov Levine, PhD, Vice President of Research at SetPoint Medical. Open to all members of the #autoimmunity and #immunology research community. Registration is required.
A team led by Michela Locci, PhD has detailed how the lipid nanoparticles that encapsulate mRNAs in vaccines—and the mRNA molecules themselves—play roles in the potency of the immune response, findings that should be useful for designing future vaccines. https://bit.ly/3MSLbkq
A new study maps kidney tissue in single cell resolution and identifies a form of disease linked to faster progression to kidney failure.
www.pennmedicine.org
events.zoom.us
This study dissects the individual contributions of the different components of mRNA
vaccines to immune responses. Nucleoside-modified mRNA promotes the production of
type I interferons that act on de...
The Colton Center for Autoimmunity, University of Pennsylvania
The Colton Center for Autoimmunity, University of Pennsylvania
The Colton Center for Autoimmunity, University of Pennsylvania
The Colton Center for Autoimmunity, University of Pennsylvania
The Colton Center for Autoimmunity, University of Pennsylvania
The Colton Center for Autoimmunity, University of Pennsylvania
The Colton Center for Autoimmunity, University of Pennsylvania
Dr. Sara Cherry shared progress from the High-Throughput Center for Autoimmune Therapeutic Discovery (HIT-AI), a Colton Center of Excellence. Working with collaborators, Dr. Fajgenbaum and Dr. Miner, the center combines #AI with high-throughput screening to identify new #autoimmune therapies.
Are you part of the #autoimmunity or #immunology research community? Join us Feb. 17 at 11 AM ET for a seminar with Yaakov Levine, PhD (SetPoint Medical), a leader in bioelectronic medicine whose work helped advance FDA-approved vagus nerve–based therapy for rheumatoid arthritis. bit.ly/LevineFeb17
